Sanofi’s Kevzara®▼ as Rheumatoid Arthritis treatment

Hannah Alderton 12 April 2018

The Scottish Medicines Consortium (SMC) issued positive advice on Sanofi’s Kevzara® (sarilumab) for routine use on the NHS in Scotland, in combination with methotrexate (MTX) for the treatment of adults with severe rheumatoid arthritis (RA) who have not responded adequately to intensive therapy with a combination of conventional Disease-Modifying-Anti-Rheumatic-Drugs (DMARDs). This decision gives severe RA patients in Scotland a further option when conventional treatments are not adequately controlling the condition.

Kevzara® (sarilumab) has also been accepted by the SMC as a monotherapy for severe RA if a patient is either intolerant to, or inappropriate for, treatment with MTX. Additionally, Kevzara® (sarilumab) can be used in combination with MTX when severe disease is inadequately controlled by a TNF agonist and patients are ineligible for treatment with rituximab

Kevzara® (sarilumab) was granted EU marketing authorisation in combination with MTX for the treatment of moderately to severely active RA in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs.7 Kevzara® (sarilumab) Sarilumab can also be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.

Gordon Boyd, Medical Director UK & Ireland at Sanofi Genzyme said, “We are delighted to see more treatments becoming available in Scotland for rheumatoid arthritis. This is a progressive disease which needs to be controlled as early as possible to prevent irreversible damage. There are still a large number of people with severe RA for whom DMARDs are not enough.”

Make a comment

To voice your opinion, please Log in or Register.

Pf Magazine

Your resource for news, features, interviews, careers and events in the pharma industry.

Click here for the latest issue and to subscribe.